Advanced search
Publication Cover
Cancer Investigation Volume 35, 2017 - Issue 9
Submit an article Journal homepage
149
Views
12
CrossRef citations to date
0
Altmetric
Article

Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients

James R. HockerDepartment of Biochemistry and Molecular biology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 940 Stanton L. Young Blvd., BMSB 853, Oklahoma City, OK, USA
,
Subrato J. DebDepartment of Surgery, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, P.O. Box Williams Pavilion Room 2140. Oklahoma City, OK, USA
,
Min LiDepartment of Surgery, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, P.O. Box Williams Pavilion Room 2140. Oklahoma City, OK, USA
,
Megan R. LernerDepartment of Surgery, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, P.O. Box Williams Pavilion Room 2140. Oklahoma City, OK, USA;Department of Veterans Affairs, Veterans Affairs Medical Center, 921 NE 13th Street, Oklahoma City, OK, USA
,
Stan A. LightfootDepartment of Veterans Affairs, Veterans Affairs Medical Center, 921 NE 13th Street, Oklahoma City, OK, USA
,
Aurelien A. QuilletDepartment of Biochemistry and Molecular biology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 940 Stanton L. Young Blvd., BMSB 853, Oklahoma City, OK, USA
,
R. Jane HanasDepartment of Biochemistry and Molecular biology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 940 Stanton L. Young Blvd., BMSB 853, Oklahoma City, OK, USA
,
Matthew ReinersmanDepartment of Surgery, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, P.O. Box Williams Pavilion Room 2140. Oklahoma City, OK, USA
,
Jess L. ThompsonDepartment of Surgery, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, P.O. Box Williams Pavilion Room 2140. Oklahoma City, OK, USA
,
Nicole T. VuAnalytical Research Laboratories BioPharma, 840 Research Parkway, Ste. 546, Oklahoma City, OK, USA
,
Thomas C. KupiecAnalytical Research Laboratories BioPharma, 840 Research Parkway, Ste. 546, Oklahoma City, OK, USA
,
Daniel J. BrackettDepartment of Veterans Affairs, Veterans Affairs Medical Center, 921 NE 13th Street, Oklahoma City, OK, USA
,
Marvin D. PeytonDepartment of Surgery, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, P.O. Box Williams Pavilion Room 2140. Oklahoma City, OK, USA
,
Stephen M. DubinettDavid Geffen School of Medicine, University of California, 10833 Le Conte Ave. CHS 37–131, Los Angeles, CA, USA
,
Harold M. BurkhartDepartment of Surgery, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, P.O. Box Williams Pavilion Room 2140. Oklahoma City, OK, USA
,
Russell G. PostierDepartment of Surgery, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, P.O. Box Williams Pavilion Room 2140. Oklahoma City, OK, USA
&
Jay S. HanasDepartment of Biochemistry and Molecular biology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 940 Stanton L. Young Blvd., BMSB 853, Oklahoma City, OK, USA;Department of Surgery, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, P.O. Box Williams Pavilion Room 2140. Oklahoma City, OK, USA;Department of Veterans Affairs, Veterans Affairs Medical Center, 921 NE 13th Street, Oklahoma City, OK, USACorrespondence[email protected]
 show all
Pages 573-585 | Received 10 Mar 2016, Accepted 25 Aug 2017, Published online: 26 Sep 2017
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

ABSTRACT

A stage I non-small cell lung cancer (NSCLC) serum profiling platform is presented which is highly efficient and accurate. Test sensitivity (0.95) for stage I NSCLC is the highest reported so far. Test metrics are reported for discriminating stage I adenocarcinoma vs squamous cell carcinoma subtypes. Blinded analysis identified 23 out of 24 stage I NSCLC and control serum samples. Group-discriminating mass peaks were targeted for tandem mass spectrometry peptide/protein identification, and yielded a lung cancer phenotype. Bioinformatic analysis revealed a novel lymphocyte adhesion pathway involved with early-stage lung cancer.

KEYWORDS:

Declaration of Interest statement

None of the co-authors have a conflict of interest pertaining to this manuscript. The co-authors have read the manuscript, contributed in an experimental and/or intellectual manner, and agree with its contents. Grant sponsors: Presbyterian Health Foundation, Oklahoma Tobacco Research Center, to J.S.H.; Grant P20RR016478 to A.M.Q., National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH).

Acknowledgments

This work was funded by the Oklahoma Center for the Advancement of Science and Technology, the Presbyterian Health Foundation, and the research funds of the University of Oklahoma Departments of Surgery and Biochemistry and Molecular Biology. We thank the Staff of the Department of Surgery for all their efforts on this study.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,193.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.